Trial Information

Long-term Safety Follow-up of REMICADE (RESULTS)

The purpose of this study is to collect long-term safety information on infliximab
(Remicade) from patients who participate in research studies using those drugs. All patients
in these studies are being asked to participate in this long-term safety follow-up study
which will provide important information about the study drug. The long-term effect of the
study drug on survival, serious infections, new malignancies and new autoimmune diseases
will be measured from data collected over a 5-year period. Additional information about
possible delayed allergic reactions (possible fever, rash, fatigue, joint pain) will also be
collected if you received infliximab (Remicade) after the end of the primary study. Study
participation in this research study is 5 years after the end of the primary study.
Questionnaires will be completed about patient's health and the occurrence of these safety
events at intervals of 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after
patients complete participation in the primary study.